The Dawn of the Age of Programmable Medicine

Many who have witnessed or participated in the birth of a child consider it akin to a miracle. There is a singular quality of hope (or if you are of a religious bent, prophecy) that surrounds birth — quieter than optimism, deeper than expectation — as though new life arrives already carrying within it the full weight of human possibility. What we don’t always allow ourselves to remember, in those first luminous hours, is that possibility and vulnerability are two sides of the same coin, written in the same biological code.

When KJ Muldoon was born on August 1, 2024, the delivery was uncomplicated and his first hours were full of the simple joy that new life brings. His three older brothers and sisters had been waiting for him with the barely-contained excitement that only children can sustain — arguments over who would hold him first, drawings taped to the refrigerator, a small delegation of opinion on what he should be named. For his first day, KJ was alert and animate, doing everything a newborn is supposed to do. And then, quietly, something changed.

On the second day of his still very new life, KJ’s vitality began to slowly dissipate. He became placid in a way that was different from sleep, uninterested in feeding, heavy in a way that was different from rest. The word that kept returning to the nurses watching him was lethargic — a clinical word that, in a newborn, carries a quiet urgency. A neonatologist took note. Years of practice had given her the instinct to look past reassuring explanations when something felt wrong, and something felt wrong. She ordered a full blood workup — and included, among the standard panels, a test for ammonia. The results, when they came back, would change everything. More tests were ordered. Specialists were called in. A precise diagnosis was soon reached.

KJ had been born with a rare metabolic disorder called carbamoyl phosphate synthetase 1 deficiency — CPS1 deficiency — a genetic disease affecting roughly one in every 1.3 million live births in the United States, or about three infants per year nationwide. Because early symptoms can easily pass beneath the initial medical radar, infants with the disorder are often discharged from the hospital, only to return days later in critical condition. Many do not survive their first week of life. KJ was fortunate that the disorder was recognized and diagnosed early, allowing immediate steps to limit its most detrimental effects. Even so, his prospects were poor. The five-year survival rate for infants with the disorder hovered around fifty percent.

CPS1 deficiency is caused by a single nucleotide mutation in the DNA sequence of the CPS1 gene — the gene responsible for producing an enzyme that detoxifies ammonia in the liver. In healthy persons, the CPS1 enzyme initiates the chemical process that converts ammonia into urea, a form of nitrogen waste that the kidneys routinely filter from the bloodstream. But the mutation KJ was born with left his CPS1 enzyme misfolded and nonfunctional. Without a working enzyme, ammonia would go unconverted, accumulate in his blood, and eventually cross into his brain, where it would become devastatingly toxic.

For decades, physicians caring for infants with CPS1 deficiency and related urea-cycle disorders had worked within the same narrow set of options: special diets designed to restrict nitrogen intake, drugs and dialysis to help clear ammonia from the bloodstream, and in many cases a race against time to find a suitable liver donor before the child’s fifth birthday. None of these approaches addressed the underlying cause of the disease. They managed the chemistry of a system broken at its genetic foundation — and even when carefully managed, the disease left children profoundly vulnerable. A simple cold could drive ammonia levels to toxic heights, triggering a crisis. Each such episode carried a mounting probability of death.

KJ may have been dealt one of nature’s crueler hands, but chance had also placed him at a remarkable moment in medical history — and that moment was taking shape in Philadelphia. Down the street from HUP — the Hospital of the University of Pennsylvania, where KJ had been born — stood the world-renowned clinical research facility Children’s Hospital of Philadelphia, known universally as CHOP. And working at CHOP were two physician-scientists who had spent years developing a therapy that, until KJ’s arrival, had never been tested in a human being.

The team was led by Dr. Kiran Musunuru, a cardiologist and geneticist, and Dr. Rebecca Ahrens-Nicklas, a specialist in pediatric metabolic disease. For two years before KJ’s birth they had been working together on the problem of in vivo base editing in the liver — not for any specific patient, nor for a specific disease, but toward the possibility of one. They had been building, in essence, a platform: a set of molecular tools and delivery systems precise enough to correct a single genetic letter in a living human being, and flexible enough to be adapted, when the moment came, to whatever mutation that patient carried. Musunuru brought the molecular architecture — the base editing systems, the genomic targeting, the biochemical delivery mechanism. Ahrens-Nicklas brought the clinical world those tools would eventually have to enter — the fragility of metabolic infants, the urgency of their timelines, the gap between what works in a laboratory and what a sick child can survive.

In principle, the idea was straightforward: correct the mutation, restore the proper folding and functionality of the enzyme, and allow the body’s own metabolic machinery to resume its work. In practice, nothing about the effort had been simple. The handful of genetic therapies that had reached human patients before this moment had followed a carefully controlled path: cells were extracted from the patient’s own body, genetically modified in the laboratory, amplified in culture, and reintroduced to the patient’s body only after passing through meticulous purification protocols. Every step of that process happened outside the body, in conditions that could be observed, measured, and corrected.

This would be something categorically different. The therapy would be delivered in vivo — directly into a living infant — which meant there would be no extraction, no controlled laboratory environment, no second chance to inspect the result before it entered the bloodstream. The molecular editors would have to find their way through the body’s circulation on their own, penetrate the right organ, enter the right cells, locate the correct gene among 3.2 billion base pairs, and rewrite the single defective letter — all without cutting the DNA strand, all without disturbing the vast surrounding code that had nothing to do with CPS1. The therapy would have to work the first time, inside a body too small and too fragile to tolerate much failure. No such treatment had ever been administered to a human being, let alone to an infant.

None of it could begin without Kyle and Nicole Muldoon, KJ’s parents.  When they agreed to a treatment conceived entirely for their son’s specific mutation — experimental, untested, unprecedented — they were placing their trust in a science that was itself still in the midst of learning what it could do. A decade earlier, what they were consenting to would have existed only in the realm of imagination. Now it was real, it was urgent, and with their informed consent, the race to produce the novel therapy began in earnest.

In the months of preparation that followed, the scientists and clinicians involved examined every aspect of the therapy with obsessive care. The formulation of the lipid nanoparticles carrying the genetic instructions had been reviewed again and again. Purity tests had been scrutinized. Manufacturing records, safety data, and quality controls — each produced under the stringent requirements of good manufacturing practice — had been checked, rechecked, and debated at length. By the time the therapy reached the hospital room, the team had gone over every detail dozens of times. On paper, the treatment made sense. The molecular design was sound. The delivery system had been validated in earlier studies. Everything suggested that it should work.

But medicine has a way of humbling even the most carefully reasoned expectations. The clinicians in the room understood how great a distance can separate what ought to work in theory from what will actually work in a human body. The lipid nanoparticles might not reach enough of KJ’s liver cells. The editing system might fail to correct the gene with sufficient efficiency. It might attempt to rewrite a base at the wrong location, introducing new harm. Unexpected immune reactions could emerge. Biology has a habit of introducing complications that no protocol can fully anticipate. Those possibilities hovered quietly in the room.

Kyle and Nicole had spent the preceding months in conversation with the doctors about these possibilities. They understood that the treatment offered hope, but no degree of certainty. In many ways, the decision had already been made by the disease itself. Without a new approach, the future for children with severe CPS1 deficiency remained grim. Now the moment had arrived when the long chain of planning and calculation would give way to something less predictable — infusion into a human being. 

On Feb. 25, 2025 – at an age just short of seven months – KJ received the first of what would eventually be three doses of the therapy.  A nurse adjusted the intravenous line connected to baby KJ’s arm, and confirmed the final measurements. The physicians exchanged brief glances — part reassurance, part acknowledgment of the unknowns that attend any first attempt. And then the infusion began, slowly. It would be three hours before the drip bag was emptied.

Inside the IV bag was a suspension of microscopic lipid nanoparticles carrying two chief molecular components. The first was a strand of mRNA encoding the base editor — the molecular machinery that would perform the actual rewriting of DNA. The second was a guide RNA, a short sequence precisely designed to navigate the editor to the single defective letter in KJ’s CPS1 gene, and nowhere else in his genome. Once absorbed by liver cells, the mRNA would be translated into the editor protein, which the guide RNA would then escort to its target — one base pair among the approximately 3.2 billion base pairs of the human genome. If the system worked as intended, KJ’s own liver cells would begin producing the enzyme his body had been missing since birth. And if enough liver cells produced enough of the CPS1 protein, KJ’s ammonia levels would fall to normal, or at least into the less dangerous range.

His fuller story will be told in Chapter 17, but the essential outcome can be stated simply: on June 3, 2025, after 307 days in hospital — the entirety of his life to that point — KJ Muldoon finally went home. He celebrated his first birthday surrounded by his family, and has since reached every developmental milestone his doctors had hoped for. Dr. Ahrens-Nicklas refrains from using the word “cure” — the condition remains carefully monitored — but she is confident in saying that the critically ill infant she first encountered in his first days of life is now a thriving, walking toddler with an entirely manageable future ahead of him.  What began as a desperate attempt to save one child’s life has become something larger: the first proof that individualized, programmable medicine is not merely a theoretical possibility, but a clinical reality — and a glimpse of what may be coming in the years ahead for the many thousands of patients for whom, until now, medicine has had no answer.

***

For much of its modern history, medicine has advanced through the discovery of drugs — molecules that alter the chemistry of the body or its invaders. Antibiotics disrupt bacterial metabolism; antihypertensive medications relax blood vessels; chemotherapy attacks rapidly dividing cells. Such drugs may inhibit enzymes, block receptors, or interfere with metabolic pathways, compensating indirectly for an underlying problem. These therapies have saved countless lives, but they act downstream of the biological instructions that govern the body. The therapy now entering KJ’s bloodstream belonged to a different category altogether. It sought not merely to influence the body’s chemistry but to rewrite its code. To treat the disease at its source.

In that quiet hospital room, the idea of programmable medicine — an idea that had been taking shape across decades of molecular biology, genetics, and biotechnology — was being tested in the life of a single child, and in doing so it drew together several scientific revolutions that had been unfolding largely in parallel for decades.

The notion that disease might be treated at the level of its molecular cause had emerged gradually during the late twentieth century, as biology itself was being transformed. The discovery of DNA’s double helix structure (1953) revealed that the instructions for life were written in a chemical language — encoded in sequences of nucleotides that directed the construction and regulation of proteins. Over the following decades, researchers learned to read that language with increasing precision. Genes responsible for inherited diseases were identified one after another, and the Human Genome Project (1990–2003) eventually produced a comprehensive map of the genetic instructions underlying human biology.

Yet for all the insight that genetics provided, the ability to alter those instructions remained elusive. For most of the twentieth century, medicine could identify the molecular origins of disease but had few ways to correct them. Gradually, scientists began to imagine a new approach: treating disease by intervening directly in the molecular machinery of the cell.

One of the earliest signs of this possibility emerged from the study of cystic fibrosis, a lethal genetic disease caused by mutations in a gene encoding a protein known as CFTR. For years, patients were treated primarily by managing the consequences of the defective protein — clearing mucus from the lungs, fighting infections, preserving respiratory function as best as possible. The underlying molecular defect was carefully studied and elucidated, but in terms of therapies it went untouched. Nevertheless, each new drug that managed CF’s deadly symptoms increased life expectancy. In the 1950s, a CF patient lived on average less than five years. By the 1970s, the median age had risen into the teens — progress that offered hope. But by the late twentieth century the median age of survival had reached the early thirties — a genuine achievement over prior decades, but still a life measured in half-measures.

In the early twenty-first century, researchers at Vertex Pharmaceuticals, among them the scientist Paul Negulescu, pursued a more ambitious idea. Rather than managing the lethal symptoms, they sought to design drugs capable of restoring the function of the defective CFTR protein itself. The effort required years of structural studies, chemical screening, and clinical trials, but the result — a combination therapy eventually known as Trikafta (approved by the FDA in 2019) — transformed the outlook for many patients with the disease, raising expectations of survival to age 65 or higher. For the first time, a drug had been designed to repair the misfolding of a protein at the center of a genetic disorder. This was slow, painstaking molecular craftsmanship — not yet programmable medicine — but a clear harbinger of the age in which therapies would address the underlying molecular cause of disease rather than merely its symptoms.

Around the same time, a quieter revolution was unfolding in cell biology — one centered not on DNA itself but on the messenger molecules that carry its instructions. RNA, long regarded primarily as a passive intermediary between gene and protein, was turning out to be something far more active and manipulable than anyone had imagined. Cells, it emerged, used RNA molecules to regulate their own gene expression, silencing some messages and amplifying others through an elaborate system of molecular switches. The question scientists began to ask was whether those same switches could be reprogrammed from outside the cell.

The answer, it turned out, was yes — and in more than one way. One particularly powerful mechanism was RNA interference (discovered 1998), a natural cellular process in which small RNA molecules act as precise molecular off-switches, silencing specific genes with remarkable selectivity. By harnessing this system, researchers learned to design synthetic RNA sequences capable of suppressing harmful genetic messages — turning off the instructions for a disease-causing protein the way one might cut a wire rather than dismantle an entire circuit. Companies such as Alnylam Pharmaceuticals (founded 2002), guided by figures including John Maraganore, helped carry RNA interference from a laboratory curiosity into an entirely new class of medicines, winning the first FDA approval for an RNAi drug in 2018.

A parallel and equally consequential breakthrough came from a different direction. Katalin Karikó had spent years as a largely overlooked researcher pursuing an idea that most of her colleagues considered a dead end: that messenger RNA could itself be used as a drug. The obstacle was formidable — the immune system recognized foreign RNA as a threat and destroyed it before it could do anything useful. Working with the immunologist Drew Weissman, Karikó discovered (2005) that chemically modifying specific building blocks of mRNA could render it invisible to that immune surveillance, allowing it to enter human cells intact and deliver its instructions. Where RNA interference silenced genes, this approach did the opposite — it gave cells new instructions to follow, directing them to manufacture therapeutic proteins they would not otherwise produce. The same strategy would later become recognized worldwide through Moderna and BioNTech’s mRNA vaccines (2020–21) that saved millions of lives during the COVID-19 pandemic, but the implications for medicine ran far deeper than any single application.

The most consequential event in the development of programmable medicine came with the discovery of CRISPR gene editing. Working independently and then in collaboration, Jennifer Doudna and Emmanuelle Charpentier uncovered (2012) the mechanism by which bacteria deploy CRISPR systems to defend against viral infection — and recognized that the same mechanism could be repurposed as a programmable tool for rewriting DNA.

Within a few years, CRISPR had transformed genetic research. Scientists working with living cells could now alter genes with a precision that had previously been unimaginable. Refinements followed swiftly, including base editing techniques developed by David Liu and his colleagues (2016), which made it possible to rewrite individual DNA letters without cutting the genetic strand.

As these tools matured, genetic correction began its passage from theoretical possibility to clinical reality. Experimental treatments using gene editing showed early promise in diseases such as sickle cell anemia, leading to the first FDA approval of a CRISPR-based therapy (2023). Beyond correcting inherited mutations, the same tools were being turned against cancer — engineered immune cells known as CAR-T cells, developed by investigators including Carl June (first human trials 2010), demonstrated that entire populations of cells could be reprogrammed to seek and destroy tumors.

Yet even the most powerful genetic tools faced a persistent obstacle: how to deliver fragile RNA or DNA molecules to the right cells inside a living body. Meeting that challenge required advances in drug delivery, and above all the development of lipid nanoparticles capable of ferrying genetic instructions into living cells. Pieter Cullis and his collaborators spent decades (1970s–2010s) refining these microscopic carriers — work that would prove essential to many of the RNA and gene-editing therapies that followed.

Each of these discoveries — precision molecular drugs, RNA-based medicines, genome editing, engineered immune cells, nanoparticle delivery — might once have appeared to be separate scientific stories. But by the time KJ was born, they had begun to converge into something larger. Taken together, they signaled that medicine was entering a new phase in its history — one in which scientists could intervene in cell biology at a more fundamental level, modifying the instructions that govern how cells function, communicate, and respond to their environment.

In that sense, the infusion flowing into KJ’s bloodstream was more than a single experimental therapy. It was the first expression of a new idea: that entire biological systems might be programmable, and that medicine could operate not merely by discovering drugs, but by designing interventions that rewrite the underlying code of life. 

This book traces the scientific path that made KJ’s treatment possible — the discoveries, the decades of incremental progress, and the occasional leaps of insight that carried medicine from identifying the genetic origins of disease to, finally, being able to correct them. But it is not exclusively a book about science.

Science, in the end, is a human enterprise, and the compelling story here is about the people who drove it forward: the researchers who spent careers pursuing ideas their colleagues dismissed, the clinicians who refused to accept that their patients had exhausted their options, and the patients themselves, whose courage and suffering gave the entire enterprise its moral urgency.

Some of those patients will become central figures in the pages that follow. Emily Whitehead was a six-year old in 2012 with a twice relapsed case of leukemia when she became the first child to receive an experimental immune cell therapy known as CAR-T — a treatment that had mostly failed in adult patients before her. Emily’s treatment set off a cytokine storm that nearly killed her, but that in the end, against all expectation, saved her life. She remains cancer-free to this day. Paul Kalanithi was a brilliant neurosurgeon who, in the months after his diagnosis with terminal lung cancer, turned his physician’s eye on his own dying body and wrote with devastating clarity about what it means to stand at the intersection of medicine’s power and its limits. And KJ Muldoon, whose story opens this book, represents something different again — not the end of a long struggle, but the beginning of a new one: the first child whose disease was met not with management, not with palliation, but with a correction written directly into his DNA.

Together, their stories — and the stories of the scientists whose work made those stories possible — trace the arc of a transformation that is still underway. Medicine is not yet what it is becoming. But it is becoming something remarkable, and this book is an attempt to understand what that means.

-Elli Sacks-
April 6, 2026
Modi’in, Israel